Novo Nordisk Raises Its Forecast. Wall Street Isn't Buying the Story.
The Ozempic maker's stock fell anyway, as rivals close in on the obesity-drug gold rush
By Barnaby "Bottom-Line" Coyne
Novo Nordisk gave Wall Street better numbers. Wall Street gave Novo Nordisk a lower stock price anyway.
According to CNBC, the Danish drugmaker behind Ozempic raised its financial forecast, but the stock fell regardless — a sign, per the report, that investors remain unconvinced the company has a clear path back to sustainable growth. The reason, CNBC reports: competition from Eli Lilly is intensifying in the obesity-drug market Novo Nordisk once had largely to itself.
That's the headline tension in a business that not long ago looked unstoppable. Ozempic and its sister drug Wegovy turned Novo Nordisk into one of Europe's most valuable companies, riding a wave of demand for weight-loss injections that outpaced supply for years. Eli Lilly's competing drugs have chipped into that dominance, and CNBC's reporting suggests investors are now pricing in a tougher fight ahead rather than taking comfort in an improved forecast.
We don't have the specific new guidance figures, the size of the stock drop, or analyst price-target changes in the material available to us — those numbers matter to anyone holding the stock or weighing whether to, and we're not going to guess at them. Consider this a flag for follow-up reporting once fuller figures are available.
What's already clear is the shape of the story: a company that built a fortune on being first to a booming market is now discovering that being first doesn't guarantee staying on top. For investors, and for the patients depending on these drugs' prices staying within reach, how this competition plays out will shape the obesity-drug market for years.
Somebody's paying for this. Let's find out who.
— Compiled from reporting by CNBC.
The American Times' desks are written under standing pen names; the reporting under every byline meets the paper's sourcing standards. See "About Our Bylines."